<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407725</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Increased Activation Markers of Adaptive Immunity in Patients with Severe COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195664</ELocationID><Abstract><AbstractText><b>Introduction:</b> COVID-19 is a pandemic disease and is widespread over the world. This disease shows a 5.1% mortality. The understanding of the disease has expanded rapidly in many areas, including virological, epidemiological, clinical, and management dimensions. To better understand the inflammatory and immune profiles that impact the pathogenesis and development of severe COVID-19 symptoms, further studies are essential. This research aims to explore the inflammatory and adaptive immune responses associated with COVID-19, considering factors such as genetic diversity and environmental exposure among Saudi patients. The goal is to determine if patients with severe COVID-19 exhibit different disease phenotypes. <b>Materials and Methods:</b> This case-control study includes 115 participants (healthy and with COVID-19 infection), 55 of which had confirmed cases of COVID-19 in intensive care units (ICUs) at different hospitals in Makkah City, Saudi Arabia. Whole blood samples were collected from June to September 2021 for cellular analyses, and inflammation marker data were collected from hospital records. The expression of activation markers on B (CD27 and CD38) and T cells (CD27 and HLA-DR) was obtained using the flow cytometry technique. Also, serum was collected for cytokine measurements, including IL-6, INF-γ, and TNF- α. <b>Results:</b> The results indicated that lymphopenia and excessive T cell activation were more prevalent in severe cases than in healthy individuals. Furthermore, the results revealed that severe COVID-19 patients had an increased frequency of CD19+ B cells, with changes in B cell subsets. The current study implies impairment and changes in the phenotype of adaptive cells (including T and B cells), with an increase in HLA-DR molecules and inflammation markers with pro-inflammatory cytokines in severe COVID-19 cases. <b>Conclusions:</b> The current study implies impairment and changes in the phenotype of adaptive cells (including T and B cells), with an increase in HLA-DR molecules and inflammation markers in severe COVID-19 cases, which could be targeted for therapeutic interventions. This might be a valuable approach for the diagnosis and treatment of severe COVID-19 cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aljuaid</LastName><ForeName>Abdulelah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TU-DSPP-2024- 69</GrantID><Agency>Taif University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B and T cells</Keyword><Keyword MajorTopicYN="N">CD markers</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adaptive immunity</Keyword></KeywordList><CoiStatement>No relevant financial relationships exist. The author declares that he has no conflicts of interest or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407725</ArticleId><ArticleId IdType="pmc">PMC11477269</ArticleId><ArticleId IdType="doi">10.3390/jcm13195664</ArticleId><ArticleId IdType="pii">jcm13195664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guarner J. Three Emerging Coronaviruses in Two Decades. Am. J. Clin. Pathol. 2020;153:420–421. doi: 10.1093/ajcp/aqaa029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa029</ArticleId><ArticleId IdType="pmc">PMC7109697</ArticleId><ArticleId IdType="pubmed">32053148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., Chiesa-Estomba C.M., Place S., Van Laethem Y., Cabaraux P., Mat Q., Huet K., Plzak J., Horoi M., Hans S., et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288:335–344. doi: 10.1111/joim.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13089</ArticleId><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Biondi-Zoccai G., Brown T.S., Der Nigoghossian C., Zidar D.A., Haythe J., et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J. Am. Coll. Cardiol. 2020;75:2352–2371. doi: 10.1016/j.jacc.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7198856</ArticleId><ArticleId IdType="pubmed">32201335</ArticleId></ArticleIdList></Reference><Reference><Citation>Allahyani M.A., Aljuaid A.A., Almehmadi M.M., Alghamdi A.A., Halawani I.F., Aldairi A.F., Alharbi A.M., Albshri M.H., Mutwalli A.A., Alhazmi A.S. Detection of erythroid progenitors and erythrocytopathies in patients with severe COVID-19 disease. Saudi Med. J. 2022;43:899–906. doi: 10.15537/smj.2022.43.8.20220311.</Citation><ArticleIdList><ArticleId IdType="doi">10.15537/smj.2022.43.8.20220311</ArticleId><ArticleId IdType="pmc">PMC9749667</ArticleId><ArticleId IdType="pubmed">35964959</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen L.A., Geldhof V., Pasut A., Carmeliet P. COVID-19: The vasculature unleashed. Nat. Rev. Immunol. 2020;20:389–391. doi: 10.1038/s41577-020-0343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., Bikdeli B., Ahluwalia N., Ausiello J.C., Wan E.Y., et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017–1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva D.P., Jacinto A., Borralho P., Braga S., Cabral M.G. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients’ Response to Neoadjuvant Chemotherapy. Front. Immunol. 2018;9:2605. doi: 10.3389/fimmu.2018.02605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02605</ArticleId><ArticleId IdType="pmc">PMC6282034</ArticleId><ArticleId IdType="pubmed">30555458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfortmueller C.A., Meisel C., Fux M., Schefold J.C. Assessment of immune organ dysfunction in critical illness: Utility of innate immune response markers. Intensive Care Med. Exp. 2017;5:49. doi: 10.1186/s40635-017-0163-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-017-0163-0</ArticleId><ArticleId IdType="pmc">PMC5653680</ArticleId><ArticleId IdType="pubmed">29063386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tippalagama R., Singhania A., Dubelko P., Lindestam Arlehamn C.S., Crinklaw A., Pomaznoy M., Seumois G., de Silva A.D., Premawansa S., Vidanagama D. HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. J. Immunol. 2021;207:523–533. doi: 10.4049/jimmunol.2100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100011</ArticleId><ArticleId IdType="pmc">PMC8516689</ArticleId><ArticleId IdType="pubmed">34193602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.H., Kumar D., Prince C., Briones M., Chandrakasan S. HLA-DR+ CD38high Expression in T Cells Is Excellent in Quantifying the Amplitude of T-Cell Activation in a Spectrum of Hyperinflammatory Disorders Including HLH. Blood. 2022;140((Suppl. S1)):8329–8330. doi: 10.1182/blood-2022-170987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-170987</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J., Wei L., Li G., Hua M., Sun Y., Wang D., Han K., Yan Y., Song C., Song R., et al. Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated with Immune Disorder and Disease Severity of COVID-19. Front. Immunol. 2021;12:735125. doi: 10.3389/fimmu.2021.735125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.735125</ArticleId><ArticleId IdType="pmc">PMC8458852</ArticleId><ArticleId IdType="pubmed">34567001</ArticleId></ArticleIdList></Reference><Reference><Citation>Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 2020;38:1–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa-Hernández V.A., Torres-Ruíz J., Cervantes-Díaz R., Romero-Ramírez S., Páez-Franco J.C., Meza-Sánchez D.E., Juárez-Vega G., Pérez-Fragoso A., Ortiz-Navarrete V., Ponce-de-León A., et al. B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Front. Immunol. 2020;11:611004. doi: 10.3389/fimmu.2020.611004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.611004</ArticleId><ArticleId IdType="pmc">PMC7744304</ArticleId><ArticleId IdType="pubmed">33343585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzer B., Trapin D., Ettel P., Kormoczi U., Rottal A., Tuppy F., Feichter M., Gattinger P., Borochova K., Dorofeeva Y., et al. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy. 2021;76:751–765. doi: 10.1111/all.14647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14647</ArticleId><ArticleId IdType="pmc">PMC7984452</ArticleId><ArticleId IdType="pubmed">33128792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan A.A., Al-Ahmed S.H., Muhammad J., Khan A., Sule A.A., Tirupathi R., Al Mutair A., Alhumaid S., Al-Omari A., Dhawan M., et al. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines. 2021;9:436. doi: 10.3390/vaccines9050436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9050436</ArticleId><ArticleId IdType="pmc">PMC8145892</ArticleId><ArticleId IdType="pubmed">33946736</ArticleId></ArticleIdList></Reference><Reference><Citation>Almehmadi M., Turjoman A., El-Askary A., Shafie A., Rebh F., Alenazi M., Giustina A. Association of vitamin D deficiency with clinical presentation of COVID-19. Eur. J. Inflamm. 2021;19:20587392211038315. doi: 10.1177/20587392211038315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20587392211038315</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G., et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19) Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol. Hepatol. 2020;5:428–430. doi: 10.1016/S2468-1253(20)30057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30057-1</ArticleId><ArticleId IdType="pmc">PMC7129165</ArticleId><ArticleId IdType="pubmed">32145190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: A review and comparisons. J. Card. Fail. 2020;26:483–485.</Citation></Reference><Reference><Citation>Cai B., Cui Y., Zhou J., Wang Y.B., Yang L., Tan B., Wang J.J. Asymmetric Hydrophosphinylation of Alkynes: Facile Access to Axially Chiral Styrene-Phosphines. Angew. Chem. Int. Ed. Engl. 2023;62:e202215820. doi: 10.1002/anie.202215820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202215820</ArticleId><ArticleId IdType="pubmed">36424372</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao B., Wu Y., Liang H., Xiao J., Han Y., Yang Z., Bi Y. C-reactive protein to lymphocyte ratio is a significant predictive factor for poor short-term clinical outcomes of SARS-CoV-2 BA.2.2 patients. Front. Public Health. 2023;11:1168375. doi: 10.3389/fpubh.2023.1168375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1168375</ArticleId><ArticleId IdType="pmc">PMC10117655</ArticleId><ArticleId IdType="pubmed">37089472</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020;63:457–460. doi: 10.1007/s11427-020-1637-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-020-1637-5</ArticleId><ArticleId IdType="pmc">PMC7089049</ArticleId><ArticleId IdType="pubmed">32009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J.W., Zhang C., Fan X., Meng F.P., Xu Z., Xia P., Cao W.-J., Yang T., Dai X.-P., Wang S.-Y., et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat. Commun. 2020;11:3410. doi: 10.1038/s41467-020-17240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17240-2</ArticleId><ArticleId IdType="pmc">PMC7343781</ArticleId><ArticleId IdType="pubmed">32641700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesenak M., Brndiarova M., Urbancikova I., Rennerova Z., Vojtkova J., Bobcakova A., Ostro R., Banovcin P. Immune Parameters and COVID-19 Infection—Associations with Clinical Severity and Disease Prognosis. Front. Cell Infect. Microbiol. 2020;10:364. doi: 10.3389/fcimb.2020.00364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00364</ArticleId><ArticleId IdType="pmc">PMC7338601</ArticleId><ArticleId IdType="pubmed">32695683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>